Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;84(8):717-722.
doi: 10.1002/pros.24687. Epub 2024 Mar 7.

Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system

Richard Bennett 4th  1   2 , Eric V Li  1 , Austin Y Ho  1 , Jonathan A Aguiar  1 , Clayton Neill  1 , Steven P Rowe  3 , Hiten D Patel  1 , Hatice Savas  4 , Ashley E Ross  1
Affiliations

Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system

Richard Bennett 4th et al. Prostate. 2024 Jun.

Abstract

Introduction: The Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides appropriate use criteria (AUC) for prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) which include guidance on imaging in newly diagnosed prostate cancer and in patients with biochemically recurrent (BCR) disease. This study aims to examine trends in PSMA implementation and the prevalence and outcomes of scans ordered in scenarios deemed rarely appropriate or not meeting SNMMI AUC.

Methods: We retrospectively identified patients who were diagnosed with presumptive National Comprehensive Cancer Network unfavorable intermediate, high, or very high risk prostate cancer, patients who underwent staging for BCR, and all patients staged with PSMA between July 2021 and March 2023. Positivity was validated by adherence to a predetermined reference standard.

Results: The frequency of PSMA use increased in initial staging from 24% to 80% and work-up of BCR from 91% to 99% over our study period. In addition, 5% (17/340) of PSMA scans ordered for initial staging did not meet AUC and 3% (15/557) of posttreatment scans were deemed rarely appropriate. Initial staging orders not meeting SNMMI AUC resulted in no positivity (0/17), while rarely appropriate posttreatment scans were falsely positive in 75% (3/4) of cases. Urologists (53%, 17/32) comprised the largest ordering specialty in rarely appropriate use.

Conclusion: The frequency of PSMA use rose across the study period. A significant minority of patients received PSMA PET/CT in rarely appropriate scenarios yielding no positivity in initial staging and significant false positivity post-therapy. Further education of providers and electronic medical record-based interventions could help limit the rarely appropriate use of PET imaging.

Keywords: PSMA PET/CT; cancer staging; diagnosis; prostate cancer.

PubMed Disclaimer

References

REFERENCES

    1. Mottet N, Bellmunt J, Bolla M, et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618‐629. doi:10.1016/j.eururo.2016.08.003
    1. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate‐specific membrane antigen PET‐CT in patients with high‐risk prostate cancer before curative‐intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208‐1216. doi:10.1016/S0140-6736(20)30314-7
    1. Calais J, Ceci F, Eiber M, et al. (18)F‐fluciclovine PET‐CT and (68)Ga‐PSMA‐11 PET‐CT in patients with early biochemical recurrence after prostatectomy: a prospective, single‐centre, single‐arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286‐1294. doi:10.1016/S1470-2045(19)30415-2
    1. Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate‐specific membrane antigen PET imaging. J Nucl Med. 2022;63(1):59‐68. doi:10.2967/jnumed.121.263262
    1. Schaeffer EM, Srinivas S, Adra N, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067‐1096. doi:10.6004/jnccn.2023.0050

MeSH terms

LinkOut - more resources